Live
Clinical OMICsHormone Cell Atlas Maps Body’s Chemical MessengersClinical OMICsSHIMMER: Routine Clinical Data Processed Into Scalable Disease State MarkersEndpoints NewsLilly obesity meds Foundayo and Zepbound to gain CVS coverageEli LillyEli Lilly Stock Heads for Record Close. CVS Weight-Loss Drug Coverage Drives It Higher. - Barron'sIlluminaIllumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research - PR NewswireThermo FisherThermo Fisher Launches E-Gel Power Snap Lite System - Contract PharmaBioPharma DiveGSK, Ionis unveil data for hepatitis B drug touted as ‘functional cure’BioWorldBreakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infectionsBioWorldTROP2 ADCs progress into first-line for lung, breast cancersBioWorldLongbio to raise HK$1.4B in Hong Kong IPO for immunology workEndpoints NewsFor wearables, it’s a GLP-1 worldEli LillyCVS restores coverage of Eli Lilly obesity med Zepbound, adds new pill Foundayo - Fierce Pharma
BioPharma Dive Apr 13, 2026

Revolution pancreatic cancer drug nearly doubles survival in key trial

Revolution pancreatic cancer drug nearly doubles survival in key trial

Original
Body unavailable. Use the original source.